WuXi PharmaTech Earnings: Here’s Why the Stock is Up Now
WuXi PharmaTech (Cayman) Inc. (NYSE:WX) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 0.08%.
WuXi PharmaTech (Cayman) Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased 39.39% to $0.46 in the quarter versus EPS of $0.33 in the year-earlier quarter.
Revenue: Rose 9.17% to $142.33 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: WuXi PharmaTech (Cayman) Inc. reported adjusted EPS income of $0.46 per share. By that measure, the company beat the mean analyst estimate of $0.39. It beat the average revenue estimate of $141.1 million.
Quoting Management: “WuXi continues to make progress in building a broad, integrated platform of R&D services that will enable anyone and any company to discover and develop medicines more efficiently and cost effectively,” said Dr. Ge Li, Chairman and Chief Executive Officer. “This integrated platform does more than simply provide convenience to clients; it helps them realize their dream of being a drug discoverer and developer.”
Key Stats (on next page)…
Revenue increased 7.93% from $131.87 million in the previous quarter. EPS increased 31.43% from $0.35 in the previous quarter.
Looking Forward: Analysts have a neutral outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings is a profit of $0.38 and has not changed. For the current year, the average estimate has moved up from a profit of $1.47 to a profit of $1.53 over the last ninety days.